Cargando…

Study of Clinical Predictive Value and Immune Characterization of SLFN11 in Clear Cell Renal Cell Carcinoma

BACKGROUND: SLFN11 has been found to regulate the development and progression of a variety of cancers and is associated with drug therapy, while its role in clear cell renal cell carcinoma (ccRCC) remains unclear; therefore, the aim of this study was to investigate SLFN11 expression in ccRCC patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yifu, Zhang, Zhicheng, Fu, Shengqiang, Wang, Siyuan, Cheng, Xiaofeng, Lei, Kunyang, Li, Zhilong, Sun, Ting, Ma, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521339/ https://www.ncbi.nlm.nih.gov/pubmed/34675634 http://dx.doi.org/10.2147/IJGM.S336823

Ejemplares similares

GRAMD1A Is a Biomarker of Kidney Renal Clear Cell Carcinoma and Is Associated with Immune Infiltration in the Tumour Microenvironment
por: Liu, Yifu, et al.
Publicado: (2022)

Prognostic Value of Long Noncoding RNA DLEU2 and Its Relationship with Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma
por: Fu, Shengqiang, et al.
Publicado: (2021)

Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response
por: Alvi, Erin, et al.
Publicado: (2023)

Identification of a Novel Myc-Regulated Gene Signature for Patients with Kidney Renal Clear Cell Carcinoma
por: Fu, Shengqiang, et al.
Publicado: (2022)

A comprehensive analysis of the prognostic value and immune infiltration of low expression DBT in clear cell renal cell carcinoma
por: Xie, Wenjie, et al.
Publicado: (2022)

Preliminary study on the role of the C5orf46 gene in renal cancer
por: Ma, Ming, et al.
Publicado: (2022)

Mechanistic understanding of human SLFN11
por: Metzner, Felix J., et al.
Publicado: (2022)

SLFN11’s surveillance role in protein homeostasis
por: Murai, Yasuhisa, et al.
Publicado: (2022)

Systematic analysis of RNASET2 gene as a potential prognostic and immunological biomarker in clear cell renal cell carcinoma
por: Liu, Yifu, et al.
Publicado: (2023)

SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
por: Mezzadra, Riccardo, et al.
Publicado: (2019)

Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development
por: Moribe, Fumiya, et al.
Publicado: (2021)

Novel amino acid metabolism‐related gene signature to predict prognosis in clear cell renal cell carcinoma
por: Cheng, Xiaofeng, et al.
Publicado: (2022)

LncRNA GAPLINC Promotes Renal Cell Cancer Tumorigenesis by Targeting the miR-135b-5p/CSF1 Axis
por: Wang, Siyuan, et al.
Publicado: (2021)

The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
por: Coleman, Niamh, et al.
Publicado: (2020)

Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma
por: Zoppoli, Gabriele, et al.
Publicado: (2015)

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
por: Murai, Junko, et al.
Publicado: (2016)

SPDR-4 SLFN11 RENDERS MEDULLOBLASTOMA SENSITIVE TO DNA DAMAGE CHEMOTHERAPIES
por: Nakata, Satoshi, et al.
Publicado: (2022)

Modulation of SLFN11 induces changes in DNA Damage response in breast cancer
por: Raynaud, Christophe Michel, et al.
Publicado: (2023)

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase
por: Garvie, Colin W., et al.
Publicado: (2021)

Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin
por: Peng, Yaojun, et al.
Publicado: (2019)

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
por: Willis, Sophie E., et al.
Publicado: (2021)

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

Robotic-assisted tumor enucleation versus robotic-assisted partial nephrectomy for intermediate and high complexity renal cell carcinoma: a single-institution experience
por: Lei, Kunyang, et al.
Publicado: (2023)

SLFN14 gene mutations associated with bleeding
por: Stapley, Rachel J., et al.
Publicado: (2019)

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
por: Winkler, Claudia, et al.
Publicado: (2021)

DNA damage-Induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs
por: Li, Manqing, et al.
Publicado: (2018)

Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer
por: Tserpeli, Victoria, et al.
Publicado: (2021)

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
por: Ballestrero, Alberto, et al.
Publicado: (2017)

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
por: Winkler, Claudia, et al.
Publicado: (2020)

SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression
por: Fischietti, Mariafausta, et al.
Publicado: (2022)

Characterization of Novel Ribosome-Associated Endoribonuclease SLFN14 from Rabbit Reticulocytes
por: Pisareva, Vera P., et al.
Publicado: (2015)

Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma
por: Fan, Bo, et al.
Publicado: (2019)

Loss of T-cell quiescence by targeting Slfn2 prevents the development and progression of T-ALL
por: Goldshtein, Aviya, et al.
Publicado: (2016)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

Bioinformatic analysis highlights SNHG6 as a putative prognostic biomarker for kidney renal papillary cell carcinoma
por: Liu, Yifu, et al.
Publicado: (2023)

Global Characterization of Immune Infiltration in Clear Cell Renal Cell Carcinoma
por: Zheng, Yan, et al.
Publicado: (2021)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2020)

Ribosome dysfunction underlies SLFN14-related thrombocytopenia
por: Ver Donck, Fabienne, et al.
Publicado: (2023)

SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway
por: Zhou, Chenhao, et al.
Publicado: (2020)

A Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence
por: Berger, Michael, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_h6utlgtsv1jd0evq1snvqtigvq